Home  »  Business   »  Short Term Estimates And Forecasts For Leap Therap...

Short Term Estimates And Forecasts For Leap Therapeutics Inc. (LPTX)

Leap Therapeutics Inc. (NASDAQ:LPTX) has a beta value of 0.60 and has seen 2.65 million shares traded in the last trading session. The company, currently valued at $48.46M, closed the last trade at $0.65 per share which meant it lost -$0.07 on the day or -9.26% during that session. The LPTX stock price is -295.38% off its 52-week high price of $2.57 and 38.46% above the 52-week low of $0.40. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.41 million shares traded. The 3-month trading volume is 777.42K shares.

The consensus among analysts is that Leap Therapeutics Inc. (LPTX) is a Buy stock at the moment, with a recommendation rating of 1.80. 0 analysts rate the stock as a Sell, while 2 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.12.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Leap Therapeutics Inc. (NASDAQ:LPTX) trade information

Sporting -9.26% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the LPTX stock price touched $0.65 or saw a rise of 17.49%. Year-to-date, Leap Therapeutics Inc. shares have moved 45.00%, while the 5-day performance has seen it change 11.98%. Over the past 30 days, the shares of Leap Therapeutics Inc. (NASDAQ:LPTX) have changed 51.36%. Short interest in the company has seen 3.2 million shares shorted with days to cover at 5.78.

Wall Street analysts have a consensus price target for the stock at $3.60, which means that the shares’ value could jump 81.94% from current levels. The projected low price target is $2.50 while the price target rests at a high of $6.00. In that case, then, we find that the current price level is -823.08% off the targeted high while a plunge would see the stock gain -284.62% from current levels.

Leap Therapeutics Inc. (LPTX) estimates and forecasts

Figures show that Leap Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -40.14% over the past 6 months, with this year growth rate of -2.13%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 14.30% and -20.00% for the next quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.60% over the past 5 years. Earnings growth for 2023 is a modest 25.40% while over the next 5 years, the company’s earnings are expected to decrease by -2.49%.

LPTX Dividends

Leap Therapeutics Inc. is expected to release its next earnings report between March 09 and March 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Leap Therapeutics Inc. (NASDAQ:LPTX)’s Major holders

Insiders own 9.26% of the company shares, while shares held by institutions stand at 45.19% with a share float percentage of 49.80%. Investors are also buoyed by the number of investors in a company, with Leap Therapeutics Inc. having a total of 85 institutions that hold shares in the company. The top two institutional holders are Perceptive Advisors Llc with over 7.95 million shares worth more than $9.14 million. As of Jun 29, 2022, Perceptive Advisors Llc held 8.03% of shares outstanding.

The other major institutional holder is Artal Group S.A., with the holding of over 4.0 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $4.6 million and represent 4.04% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.31% shares in the company for having 2.29 million shares of worth $2.63 million while later fund manager owns 0.84 million shares of worth $0.97 million as of Jun 29, 2022, which makes it owner of about 0.85% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts